Our reportable segments are Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations for infectious disease products in Cincinnati, Ohio and Quebec City, Canada, manufacturing operations for products detecting elevated lead levels in blood in Billerica, Massachusetts (near Boston), and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; and Luckenwalde, Germany, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides,

and bioresearch reagents domestically and abroad, including a sales and business development facility in Beijing, China to further pursue growing revenue opportunities in Asia

Revenues from individual customers constituting

% or more of consolidated net revenues are as follows:


Year Ended September 30,	2019				2018				2017
Customer A	$	18,096	(9	)%	$	21,162	(10	)%	$	22,397	(11	)%
Customer B	$	17,350	(9	)%	$	22,490	(11	)%	$	17,825	(9	)%

Accounts receivable from these two Diagnostics customers accounted for 13% and 12% of consolidated accounts receivable at September 30, 2019 and September 30, 2018, respectively. The Company’s international revenues totaled approximately $76,430, $72,548 and $66,682 in fiscal 2019, 2018 and 2017, respectively, and our three major product families – gastrointestinal, respiratory illnesses and blood chemistry – accounted for 57%, 59% and 60% of consolidated net revenues in fiscal 2019, 2018 and 2017, respectively. We currently purchase on a sole-source basis from a U.S. manufacturer the instruments on which our Alethia molecular testing platform operates. Additionally, two of our foodborne products sourced from another vendor accounted for 9%, 9% and 10% of third-party revenues for our Diagnostics segment in fiscal 2019, 2018 and 2017, respectively.

Significant revenue information by country for the Diagnostics and Life Science segments is as follows. Revenues are attributed to the geographic area based on the location to which the product is delivered.


Year Ended September 30,	2019		2018		2017
United States	$	105,648	$	120,555	$	114,494
Italy		10,898		10,398		9,004
France		2,442		2,353		1,845
United Kingdom		2,397		2,340		1,778
Puerto Rico		2,276		1,054		730
Japan		1,571		1,307		2,421
Belgium		1,465		1,711		1,507
Holland		1,411		1,454		1,290
Other countries		8,574		9,282		10,452

Total Diagnostics	$	136,682	$	150,454	$	143,521

Year Ended September 30,	2019		2018		2017
United States	$	18,936	$	20,468	$	19,595
Germany		12,664		8,108		7,406
China		8,460		8,347		5,898
United Kingdom		4,714		5,201		5,579
Spain		4,415		4,187		3,209
Australia		3,461		3,631		4,002
France		2,200		2,040		1,792
Japan		1,624		1,932		1,375
Italy		1,357		971		700
South Korea		1,134		2,044		2,308
Other countries		5,367		6,188		5,386

Total Life Science	$	64,332	$	63,117	$	57,250

In locations outside the U.S., the Company’s identifiable assets were concentrated as follows at the end of most recent fiscal years:

As of September 30, 2019

: U.K – $22,963

; Germany – $

7,141

; Italy – $

7,557

; and Australia – $

1,392

As of September 30, 2018

: U.K – $14,816; Germany – $7,706; Italy – $7,334; and Australia – $3,543

Segment information for the interim periods is as follows:


	Diagnostics		Life Science		Corporate (1)			Eliminations (2)			Total
Fiscal 2019
Net revenues -
Third-party	$	136,682	$	64,332	$	—		$	—		$	201,014
Inter-segment		462		361		—			(823	)		—
Operating income		22,399		20,572		(10,373	)		101			32,699
Depreciation and amortization		7,676		2,288		—			—			9,964
Capital expenditures		2,049		1,748		—			—			3,797
Goodwill		70,395		18,846		—			—			89,241
Other intangible assets, net		59,807		436		—			—			60,243
Total assets		255,169		70,392		—			(83	)		325,478

Fiscal 2018
Net revenues -
Third-party	$	150,454	$	63,117	$	—		$	—		$	213,571
Inter-segment		392		397		—			(789	)		—
Operating income		32,569		13,799		(15,076	)		292			31,584
Depreciation and amortization		6,557		2,131		—			—			8,688
Capital expenditures		2,477		1,724		—			—			4,201
Goodwill		35,213		19,424		—			—			54,637
Other intangible assets, net		22,068		1,045		—			—			23,113
Total assets		180,978		70,341		—			58			251,377

Fiscal 2017
Net revenues -
Third-party	$	143,521	$	57,250	$	—		$	—		$	200,771
Inter-segment		389		537		—			(926	)		—
Operating income		34,124		14,086		(11,097	)		269			37,382
Depreciation and amortization		7,037		2,053		—			—			9,090
Capital expenditures		2,554		1,913		—			—			4,467
Goodwill		35,213		19,713		—			—			54,926
Other intangible assets, net		24,973		1,731		—			—			26,704
Total assets		180,226		69,938		—			(387	)		249,777

(1)	Includes Restructuring and Selected Legal Costs of $2,596, $7,779 and $762 in fiscal years 2019, 2018 and 2017, respectively.

(2)	Eliminations consist of inter-segment transactions.

A reconciliation of segment operating

income

to consolidated earnings before income taxes for the years ended September 30, 2019, 2018 and 2017 is as follows:


Year Ended September 30,	2019			2018			2017
Segment operating income	$	43,072		$	46,660		$	48,479
Corporate expenses		(10,373	)		(15,076	)		(11,097	)
Interest income		681			418			171
Interest expense		(1,945	)		(1,520	)		(1,642	)
Other, net		122			(102	)		518

Consolidated earnings before income taxes	$	31,557		$	30,380		$	36,429

Transactions between segments are accounted for at established intercompany prices for internal and management purposes with all intercompany amounts eliminated in consolidation.